Cue Health (HLTHQ) Osake Kurssi
Cue Health Kurssi
Viimeisten 4 vuoden aikana Cue Healthn liikevaihto kasvoi 81,1 % vuodessa ja ylsi 70,94 M USD:een. Cue Healthn nettomarginaali −526,5 % on laskenut verrattuna −312,1 %:iin muutama vuosi sitten.
Cue Health osakekurssi
Cue Health liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Cue Health -osakkeesta
The business model of Cue Health Inc is centered around the development and commercialization of diagnostic products for professional and consumer use. Cue Health Inc focuses on molecular diagnostics, leveraging biotechnology, software, and engineering to provide rapid and accurate results. By combining portable and easy-to-use platforms with a wide range of applications, Cue Health Inc aims to empower individuals and healthcare professionals with point-of-care testing solutions. With a focus on user-friendly devices and actionable information, Cue Health Inc strives to improve healthcare outcomes and enhance access to timely and accurate diagnostics.
Cue Health Inc is primarily active in the healthcare industry.
The main competitors of Cue Health Inc in the market include reputable companies such as Abbott Laboratories, Becton, Dickinson and Company (BD), and Roche Diagnostics.
Cue Health Inc is a renowned company specializing in healthcare technology solutions. Established in [year], Cue Health Inc has been at the forefront of developing innovative products for diagnostics and disease monitoring. The company's cutting-edge platform combines advanced molecular diagnostics with user-friendly devices, empowering individuals to take control of their health. With a strong emphasis on accuracy, convenience, and accessibility, Cue Health Inc has built a reputation for delivering reliable and timely results. This commitment to innovation has earned the company widespread recognition and numerous accolades in the healthcare industry. Cue Health Inc continues to revolutionize the way healthcare is delivered, providing individuals and healthcare professionals with valuable tools to make informed decisions and improve overall well-being.
Cue Health Inc has achieved several significant milestones. Notably, the company received Emergency Use Authorization from the U.S. FDA for its rapid, portable COVID-19 test. Cue Health Inc also secured a partnership with the U.S. Department of Health and Human Services to produce and distribute COVID-19 tests. Moreover, the company successfully completed a $100 million funding round, allowing for further expansion and development of its innovative technologies. Additionally, Cue Health Inc has received recognition for its advancements in diagnostics, including winning the 2020 Fast Company's Innovation by Design Award.
Cue Health Inc is primarily present in the United States of America (USA).
Cue Health Inc represents a commitment to improving healthcare access and outcomes. The company's corporate philosophy revolves around technological innovation, convenience, and empowering individuals to take control of their health. By developing portable diagnostic devices and digital health solutions, Cue Health aims to democratize healthcare by providing accurate and timely results at the point of care. With a focus on collaborations and partnerships, Cue Health Inc strives to leverage its cutting-edge technology to revolutionize the way healthcare is delivered. This dedication to innovation and accessibility makes Cue Health Inc a leading player in the healthcare industry.
8 analyytikkoa arvioi tällä hetkellä Cue Health-osaketta: 0 suosittaa ostoa, 3 pitoa ja 5 myyntiä. Vuodelle 2026 analyytikot odottavat Cue Health-yhtiöltä 213,56 M USD liikevaihtoa ja −0,22 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Cue Health-osake noteerataan hintaan 0,00 EUR (0,00 USD).
Cue Health-osake (HLTHQ) on listattuna 1 pörssissä, muun muassa: NASDAQ (HLTH).
Cue Health Inc is a company specializing in the development of innovative medical devices and services that allow for rapid and accurate diagnosis of infectious diseases and other conditions. The company was founded in 2010 and is headquartered in San Diego, California. Cue Health has multiple business segments, including diagnostics, digital health, consumer health products, clinical trials, and distributors. These business segments offer a wide range of products and services for various markets and customers. One of Cue Health's core areas is the development and manufacturing of diagnostic devices for use in clinical practice and home use. Cue Health's flagship product is the Cue Health Monitoring Test, a handheld device that enables self-testing for a variety of health conditions, including COVID-19, influenza, and Strep-A diseases. The test can provide accurate results within minutes, speeding up decision-making for medical personnel and improving healthcare for patients. Another business segment of Cue Health is digital health. The company develops apps and platforms for remote medical monitoring and surveillance. For example, the company has developed an app that allows users to manage their health data and test results on their mobile devices. The platform also enables remote monitoring by medical professionals, which can improve patient care and treatment. Cue Health also has a consumer health product line that focuses on the needs and health issues of consumers. These products are sold in retail stores and online and include a variety of health and wellness products such as vitamins, supplements, and pain relievers. Another important business segment of Cue Health is supporting clinical trials by providing diagnostic devices and services. By collaborating with medical researchers and companies, Cue Health can play a crucial role in accelerating the development of new drugs and therapies. In addition to its business segments, Cue Health is also a major distributor of medical devices and accessories. The company works with other industry leaders to offer its customers a comprehensive range of health products and services. Overall, Cue Health has a wide range of business segments and products. The company aims to improve people's lives through better healthcare and technology. With its innovative products and services, Cue Health has taken on an important role in improving global healthcare and is expected to continue growing and expanding in the coming years.
odotettu liikevaihto Cue Health on 213,56 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Cue Health on −33,59 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Cue Health:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,00. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cue Health-osakkeen arvostusta.
Cue Health:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,00. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cue Health-osakkeen arvostuskennuslukuna.
Cue Health:n Eulpool-laatuscore on 2/10.
Cue Health:n ISIN on US2297901009. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Cue Health:n ticker on HLTHQ. Tämä pörssinoteeraus käytetään Cue Health-osakkeiden kauppaan pörssissä.
Cue Health osake
Cue Health vertaisryhmä
Cue Health Ticker
Cue Health FIGI
Kaikki tunnusluvut ja syvällinen analyysi Cue Health:sta
Meidän osakeanalyysimme Cue Health-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Cue Health:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: